Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1

Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1

Recent clinical trials utilizing antigen-pulsed dendritic cells (DCs) have demonstrated increased survival of vaccinated cancer patients. Besides, the cytoplasmic transduction peptide (CTP) not only has an excellent transcellular efficiency but also shows a strong tendency to remain in the cytoplasm...

Full description

Bibliographic Details
Main Authors: Young-Hee Kim, Thi-Anh-Thuy Tran, Thi-Hoang-Oanh Duong, Shin Jung, In-Young Kim, Kyung-Sub Moon, Woo-Youl Jang, Hyun-Ju Lee, Je-Jung Lee, Tae-Young Jung
Format: Article
Language:English
Published: Taylor & Francis Group 2020-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
cytoplasmic transduction peptide (ctp)-fused protein antigen
wt1
birc5
anti-pd1
glioblastoma
Online Access:http://dx.doi.org/10.1080/21645515.2020.1732165

Internet

http://dx.doi.org/10.1080/21645515.2020.1732165

Similar Items